Time-to-treatment of diffuse large B-cell lymphoma in São Paulo (2014)
- Authors:
- USP affiliated author: PEREIRA, JULIANA - FM
- School: FM
- DOI: 10.6061/clinics/2014(05)12
- Subjects: LINFOMA; PROGNÓSTICO; LINFÓCITOS B; SAÚDE PÚBLICA; DIAGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
XAVIER, Flávia Dias; LEVY, Debora; PEREIRA, Juliana. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. Clinics, São Paulo, v. 69, n. 5, p. 367-371, 2014. Disponível em: < http://www.scielo.br/pdf/clin/v69n5/1807-5932-clin-69-05-367.pdf > DOI: 10.6061/clinics/2014(05)12. -
APA
Xavier, F. D., Levy, D., & Pereira, J. (2014). Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. Clinics, 69( 5), 367-371. doi:10.6061/clinics/2014(05)12 -
NLM
Xavier FD, Levy D, Pereira J. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo [Internet]. Clinics. 2014 ; 69( 5): 367-371.Available from: http://www.scielo.br/pdf/clin/v69n5/1807-5932-clin-69-05-367.pdf -
Vancouver
Xavier FD, Levy D, Pereira J. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo [Internet]. Clinics. 2014 ; 69( 5): 367-371.Available from: http://www.scielo.br/pdf/clin/v69n5/1807-5932-clin-69-05-367.pdf - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
- Clinical prognostic models in diffuse large B cell lymphoma patients are still essencial in the rituximab era
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
Informações sobre o DOI: 10.6061/clinics/2014(05)12 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
